Cancer cells have variable levels of sensitivity to TRAIL-mediated apoptosis[10] and studies have shown that IFNγ pre-treatment can sensitize some of the resistant cancer lines to TRAIL[11–15]. This evidence concerns the gene TNFSF10 and cancer.